Abstract:Streptococcus salivarius is a gram-positive, non-pathogenic bacteria found in the oral cavity and upper respiratory tract. This bacterium has been shown to possess antimicrobial properties with the potential to cause activation of natural killer (NK) cells and induction of anti-tumorigenic cytokines such as interferon-gamma and interleukin-12 (IL-12). There is a high abundance of this bacteria in the saliva in oral squamous cell carcinoma patients. Moreover, Streptococcus-reactive cytotoxic T cells were associated with recurrence-free survival. Nevertheless, there is a considerable lack of information regarding the impact of S. salivarius on intratumoral immune responses and its potential as a cancer therapeutic. This study aimed to characterize the immune responses in the tumor microenvironment by S. salivarius in combination with programmed cell death protein 1 (anti-PD-1) therapy and its therapeutic efficacy. We expect that S. salivarius will cooperate with immune checkpoint inhibitors, activating antitumor immune responses. For this project, we used a preclinical murine model where an HPV+ oropharyngeal cancer cell line named mEER was implanted subcutaneously or in the tongue of the mice. We treated with or without S. salivarius and/or anti-PD-1. First, S. salivarius was administered intratumorally on subcutaneous tumors and treated or not with anti-PD-1 therapy administered intraperitoneally. We measured tumor volume and quantified different immune cells by flow cytometry. While anti-PD-1 treated mice showed a continuous increase in tumor volume, the ones treated with anti-PD-1 and S. salivarius reduced the growth rate starting at day 20. Mice treated with anti-PD1 and S. salivarius showed increased CD4+ T cells and myeloid-derived suppressor cells (MDSCs) compared to anti-PD-1 treatment alone. Secondly, we implanted the mice with tongue tumors and applied S. salivarius topically in the oral cavity with or without anti-PD-1. The use of S. salivarius contributed to an increase in CD4+T cells and activation of CD8+T cells and NK cells. The combination of anti-PD-1 with S. salivarius did not further enhance the activation of these cells. Nevertheless, 80% of mice receiving anti-PD-1 with S. salivarius responded to the therapy, whereas 63% responded while receiving only anti-PD-1. In conclusion, Streptococcus salivarius as a probiotic, affected tumor development and immune cell infiltration in oropharyngeal cancer. Future analyses will allow us to explore the effect of the probiotic on the tumor microenvironment and improve colonization in the oral cavity. Citation Format: Jennifer Diaz, Michael Rivera, Kamila A. Del Valle, Edna E. Piñero, Filipa Vitorino, Jorge R. Ortiz, Stephanie M. Estremera. Therapeutic efficacy by Streptococcus salivarius as a probiotic in a preclinical model of oropharyngeal carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1181.

Exploiting the Acidic Extracellular pH: Evaluation of Streptococcus salivarius M18 Postbiotics to Target Cancer Cells

Cell-free supernatant of Streptococcus salivarius M18 impairs the pathogenic properties of Pseudomonas aeruginosa and Klebsiella pneumonia

Characterization of Streptococcus salivarius as New Probiotics Derived From Human Breast Milk and Their Potential on Proliferative Inhibition of Liver and Breast Cancer Cells and Antioxidant Activity

Growth Suppression of Oral Squamous Cell Carcinoma Cells by Lactobacillus Acidophilus

Abstract 1181: Therapeutic efficacy by Streptococcus salivarius as a probiotic in a preclinical model of oropharyngeal carcinoma

Proteinaceous Secretory Metabolites of Probiotic Human Commensal Enterococcus hirae 20c, E. faecium 12a and L12b as Antiproliferative Agents Against Cancer Cell Lines

Postbiotics as Promising Tools for Cancer Adjuvant Therapy

Efficacy of probiotics, paraprobiotics, and postbiotics in colorectal cancer cell line and their role in immune response

Bioprophylactic potential of novel human colostrum probiotics via apoptotic induction of colon cancer cells and cell immune activation

Probiotics and live biotherapeutic products aiming at cancer mitigation and patient recover

Probiotics and the Role of Dietary Substrates in Maintaining the Gut Health: Use of Live Microbes and Their Products for Anticancer Effects against Colorectal Cancer

The inhibitory effects of probiotics on colon cancer cells: in vitr o and in vivo studies

Effects of Probiotic Culture Supernatant on Cariogenic Biofilm Formation and RANKL-Induced Osteoclastogenesis in RAW 264.7 Macrophages

Evaluation of the Cytotoxicity of Secondary Bioactive Compounds Produced by Streptomyces in Soil against a Colon Cancer Cell Line

Unveiling the Novel Benefits of Co-Administering Butyrate and Active Vitamin D3 in Mice Subjected to Chemotherapy-Induced Gut-Derived Pseudomonas aeruginosa Sepsis

Application of Prebiotics and Probiotics to Improve Oral and Dental Health by Inhibiting Streptococcus mutans

In Vitro Screening of Lactiplantibacillus Plantarum with Probiotic Properties and Anti-Colon Cancer Potential

Appraisal of postbiotics in cancer therapy

The Potential Role of Prebiotics, Probiotics, and Synbiotics in Adjuvant Cancer Therapy Especially Colorectal Cancer

Anti-proliferative and Anti-metastatic Potential of High Molecular Weight Secretory Molecules from Probiotic Lactobacillus Reuteri Cell-Free Supernatant Against Human Colon Cancer Stem-Like Cells (HT29-ShE)

Investigation of probiotic bacteria as dental caries and periodontal disease biotherapeutics